Clinical Trial Update: Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating mesalamine pellet formulation to maintain remission in mild to moderate ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• mesalamine pellet formulation (mesalamine)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED